AALL2131 An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
AALL2131
What is the goal of the study?
AALL2131 is a multi-center, international clinical trial designed to improve outcomes and reduce treatment-related toxicity in pediatric patients with newly diagnosed Ph+ or ABL-class Ph-like B-ALL. This study builds on the recent discovery that the addition of blinatumomab improves outcomes for patients with SR-non-Ph+ BALL, by replacing traditional cytotoxic consolidation chemotherapy with three cycles of the bispecific T-cell engager blinatumomab, combined with a continuous TKI, via a modified BFM backbone. The primary objectives are to estimate 3-year event-free survival (EFS) and to characterize the safety and toxicity profile of this regimen.
Who can participate in the study?
Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia